The South Australian immunoGENomics Cancer Institute (SAiGENCI) will be the state’s world-class cancer research institute, jointly resourced by an alliance of the Federal Department of Health, the Central Adelaide Local Health Network and the University of Adelaide. With an explicitly translational remit, the purpose of the new Institute is to focus on cancer research and clinical trials that will bring new cutting-edge technologies in immunotherapies and genomics to Adelaide. SAiGENCI will allow for coordinated collaboration in the fight to control cancer and explore a cure, by attracting and retaining brilliant biomedical and clinical researchers and collaborating externally with likeminded centres of excellence across the globe.
VIEW